Completed PHASE1 INTERVENTIONAL 2-arm NCT02992236

Effects of the NO-synthase Inhibitor VAS203 on Renal Function in Healthy Volunteers

Sponsor: Winicker Norimed GmbH

Conditions Renal Function Impairment in Healthy Volunteers

Updated 9 times since 2017 Last updated: Aug 8, 2019 Started: Aug 31, 2015 Primary completion: May 31, 2016 Completion: Nov 30, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Renal Function Impairment in Healthy Volunteers and is currently completed. Winicker Norimed GmbH leads this study, which shows 9 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Aug 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2023 — Aug 2023 [monthly]

Completed PHASE1
Dec 2022 — Jan 2023 [monthly]

Completed PHASE1

▶ Show 4 earlier versions

Jan 2021 — Dec 2022 [monthly]

Completed PHASE1
Sep 2019 — Jan 2021 [monthly]

Completed PHASE1
Jun 2018 — Sep 2019 [monthly]

Completed PHASE1
Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

Aug 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Winicker Norimed GmbH
veriNOS operations GmbH

Data source: veriNOS operations GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Erlangen, Germany